DaVita Inc. $DVA Shares Sold by Berkshire Hathaway Inc

Berkshire Hathaway Inc cut its holdings in DaVita Inc. (NYSE:DVA) by 4.8% in the 3rd quarter, according to its most recent 13F filing with the SEC. The firm owned 32,160,579 shares of the company’s stock after selling 1,635,962 shares during the period. DaVita comprises approximately 1.6% of Berkshire Hathaway Inc’s holdings, making the stock its 11th biggest position. Berkshire Hathaway Inc owned 45.55% of DaVita worth $4,273,176,000 as of its most recent SEC filing.

A number of other institutional investors have also modified their holdings of the business. Invesco Ltd. lifted its holdings in DaVita by 2.0% in the third quarter. Invesco Ltd. now owns 1,679,248 shares of the company’s stock worth $223,122,000 after acquiring an additional 32,358 shares during the last quarter. Dimensional Fund Advisors LP grew its holdings in shares of DaVita by 8.8% during the third quarter. Dimensional Fund Advisors LP now owns 1,085,593 shares of the company’s stock valued at $144,230,000 after purchasing an additional 88,061 shares during the last quarter. Arrowstreet Capital Limited Partnership grew its holdings in shares of DaVita by 109.7% during the third quarter. Arrowstreet Capital Limited Partnership now owns 553,809 shares of the company’s stock valued at $73,585,000 after purchasing an additional 289,725 shares during the last quarter. Neuberger Berman Group LLC raised its position in shares of DaVita by 138.5% during the 3rd quarter. Neuberger Berman Group LLC now owns 463,250 shares of the company’s stock worth $61,502,000 after purchasing an additional 269,015 shares during the period. Finally, Nordea Investment Management AB lifted its holdings in shares of DaVita by 1.8% in the 3rd quarter. Nordea Investment Management AB now owns 286,585 shares of the company’s stock worth $37,864,000 after purchasing an additional 5,193 shares during the last quarter. Institutional investors own 90.12% of the company’s stock.

Analysts Set New Price Targets

DVA has been the subject of a number of analyst reports. Truist Financial set a $158.00 price objective on DaVita in a research report on Thursday, February 5th. Weiss Ratings reiterated a “hold (c)” rating on shares of DaVita in a research note on Monday, December 29th. TD Cowen reissued a “hold” rating on shares of DaVita in a report on Tuesday, February 3rd. Zacks Research raised shares of DaVita from a “hold” rating to a “strong-buy” rating in a report on Wednesday, February 4th. Finally, Wall Street Zen upgraded shares of DaVita from a “hold” rating to a “buy” rating in a research report on Saturday, February 21st. One equities research analyst has rated the stock with a Strong Buy rating, one has issued a Buy rating, four have assigned a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the company presently has an average rating of “Hold” and an average price target of $155.80.

DaVita Price Performance

Shares of DaVita stock opened at $150.67 on Friday. DaVita Inc. has a 1-year low of $101.00 and a 1-year high of $159.42. The business’s fifty day moving average price is $131.81 and its two-hundred day moving average price is $127.09. The company has a market capitalization of $10.06 billion, a P/E ratio of 15.20, a PEG ratio of 0.53 and a beta of 0.94.

DaVita (NYSE:DVA) last released its quarterly earnings results on Monday, February 2nd. The company reported $3.40 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.24 by $0.16. The company had revenue of $3.62 billion during the quarter, compared to analysts’ expectations of $3.51 billion. DaVita had a negative return on equity of 413.18% and a net margin of 5.47%.The company’s revenue for the quarter was up 9.9% compared to the same quarter last year. During the same quarter in the prior year, the business posted $2.24 earnings per share. DaVita has set its FY 2026 guidance at 13.600-15.00 EPS. On average, research analysts expect that DaVita Inc. will post 10.76 earnings per share for the current fiscal year.

About DaVita

DaVita Inc (NYSE: DVA) is a leading provider of kidney care services, specializing in the management and operation of outpatient dialysis centers for patients with chronic kidney failure and end-stage renal disease. Headquartered in Denver, Colorado, the company offers a comprehensive suite of treatment modalities, including in-center hemodialysis, peritoneal dialysis, and home dialysis therapies. In addition to its core dialysis services, DaVita provides patient education, nutritional counseling, vascular access management and related laboratory services to support kidney health and overall patient well-being.

Since its formation in the mid-1990s through a clinical management services spin-off, DaVita has expanded both organically and through strategic partnerships and acquisitions.